Text Size

Walking Speeds in Patients With Chronic Obstructive Pulmonary Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Roger Goldstein, West Park Healthcare Centre
ClinicalTrials.gov Identifier:
NCT01768754
First received: January 9, 2013
Last updated: March 8, 2013
Last verified: March 2013
History of Changes
  Purpose

A growing body of evidence suggests that in individuals with chronic lung disease their walk speed is related to their daily function and quality of life. It is possible to assess their usual (routine) and fast walking speeds by getting them to walk in a flat hallway.

In individuals with chronic lung disease, we anticipate that their usual walk speed will be helpful in exercise prescription and use in multidimensional scoring systems. However, it is important to first determine the measurement properties of these two walk speeds.


Condition Intervention
Chronic Obstructive Pulmonary Disease
 Behavioral: Usual and Fast Walking Speeds

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Repeatability and Utility of the Usual and Fast Walking Speeds in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by West Park Healthcare Centre:

Primary Outcome Measures:
  • Coefficient of repeatability for usual and fast walk speeds [ Time Frame: At baseline and over 1 week period. ] [ Designated as safety issue: No ]

    Participants will be asked to demonstrate their usual and fast walk speeds over the middle 10 meters of a 30 meter straight track using optical sensors and a hand-held stopwatch. Participants will be instructed to walk at their 'usual' and 'fast' speeds as standardized instructions. The walk test will be repeated after a 5 minute rest and then repeated on two subsequent days, at the same time of day, within one week. This will be simply observational in nature with no planned intervention aside for controlling walking environment.

    The primary outcome is going to report a change in walk speeds from baseline and at 1 and 2 days using repeated measures as described by Bland and Altman (reference below).



Secondary Outcome Measures:
  • Agreement in walk speeds between optical sensors and stopwatch [ Time Frame: Baseline and over 1 week of testing. ] [ Designated as safety issue: No ]
    Assess agreement between the use of optical sensors and stop watch time for the usual and fast walk speeds.

  • Agreement in the Bode Index using six minute walk distance and usual walk speed. [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    To assess agreement in the calculated Bode Index using the six minute walk distance versus estimated usual walk speed distance over 6 minutes.


Other Outcome Measures:
  • Precision of achieving a targeted endurance time using the usual and fast walking speeds. [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    The usual and fast walk speeds will be used to predict the test speed for a high-intensity constant-speed endurance test that will achieve an acceptable endurance time of 2-15 minutes.


Enrollment: 29
Study Start Date: July 2012
Study Completion Date: March 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
COPD patients
Usual and Fast Walking Speeds
 Behavioral: Usual and Fast Walking Speeds
Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with stable moderate-severe COPD will be recruited from those under the care of a respirologist at West Park Health Care Centre

Criteria

Inclusion Criteria:

  • Clinical and spirometric diagnosis of COPD
  • Able to provide written informed consent

Exclusion Criteria:

  • Unstable cardiovascular disease
  • Acute respiratory exacerbation within 4 weeks
  • Neurologic or orthopedic limitation to walking
  • Inability to comprehend instructions in English
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01768754

Locations
Canada, Ontario
Westpark Health Care Centre
Toronto, Ontario, Canada, M6M 2J5
Sponsors and Collaborators
West Park Healthcare Centre
Investigators
Principal Investigator: Roger Goldstein, MD, FRCPC Westpark Healthcare Centre
  More Information

Publications:

Responsible Party: Roger Goldstein, Director, Respiratory Medicine, West Park Healthcare Centre
ClinicalTrials.gov Identifier: NCT01768754     History of Changes
Other Study ID Numbers: Goldstein_Walk_COPD
Study First Received: January 9, 2013
Last Updated: March 8, 2013
Health Authority: Canada: Ethics Review Committee
Canada: Health Canada
Canada: Ministry of Health & Long Term Care, Ontario

Keywords provided by West Park Healthcare Centre:
Exercise testing
Functional status
Pulmonary rehabilitation

Additional relevant MeSH terms:
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 19, 2013